Literature DB >> 30222419

A Trial Activation Initiative to Accelerate Trial Opening in an Academic Medical Center.

Yun Jung Choi1, HyeJung Jeon1, Sinae Kim1, YunJeong In1, Soo Yeon Park1, MiYeon Park1, Sumi Park1, YooMi Lee1, Sulhwa Kim1, Kyu-Pyo Kim1,2, Ha Yeong Koo1, Tae Won Kim1,2.   

Abstract

Delays in trial opening should be considered critical for the sake of not only the sponsor but the patients, as they may result in inequities of care. The Asan Medical Center, in Seoul, Korea, implemented a trial activation initiative in July 2012, in an aim to expedite the trial initiation timeline. Time intervals between trial initiation steps and the rate of institutional review board (IRB) and clinical trial agreement (CTA) parallel submission were assessed. A higher rate of parallel IRB and CTA submissions was observed after initiative implementation (25.5% vs 52.3%; P < .001). Initiative applications were shown to significantly accelerate the median trial opening time, from 114 to 81 days ( P < .001). Strategic processing of parallel submissions greatly shortened the median time required for trial initiation from 117 to 61 days compared with sequential submissions ( P < .001). A trial activation initiative including parallel IRB and CTA submissions is an effective tool for accelerating trial commencements.

Entities:  

Keywords:  clinical trial agreement; contract; cycle time; parallel submissions; study start up

Year:  2015        PMID: 30222419     DOI: 10.1177/2168479014554399

Source DB:  PubMed          Journal:  Ther Innov Regul Sci        ISSN: 2168-4790            Impact factor:   1.778


  2 in total

1.  Activating clinical trials: a process improvement approach.

Authors:  Diego A Martinez; Athanasios Tsalatsanis; Ali Yalcin; José L Zayas-Castro; Benjamin Djulbegovic
Journal:  Trials       Date:  2016-02-24       Impact factor: 2.279

2.  Drivers of Start-Up Delays in Global Randomized Clinical Trials.

Authors:  Jennifer Lai; Leila Forney; Daniel L Brinton; Kit N Simpson
Journal:  Ther Innov Regul Sci       Date:  2020-09-21       Impact factor: 1.778

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.